Czech multicenter research database of severe COPD

Barbora Novotna, Vladimir Koblizek, Jaromir Zatloukal, Marek Plutinsky, Karel Hejduk, Zuzana Zbozinkova, Jiri Jarkovsky, Ondrej Sobotik, Tomas Dvorak, Petr Safranek, Barbora Novotna, Vladimir Koblizek, Jaromir Zatloukal, Marek Plutinsky, Karel Hejduk, Zuzana Zbozinkova, Jiri Jarkovsky, Ondrej Sobotik, Tomas Dvorak, Petr Safranek

Abstract

Purpose: Chronic obstructive pulmonary disease (COPD) has been recognized as a heterogeneous, multiple organ system-affecting disorder. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) places emphasis on symptom and exacerbation management. The aim of this study is examine the course of COPD and its impact on morbidity and all-cause mortality of patients, with respect to individual phenotypes and GOLD categories. This study will also evaluate COPD real-life patient care in the Czech Republic.

Patients and methods: The Czech Multicentre Research Database of COPD is projected to last for 5 years, with the aim of enrolling 1,000 patients. This is a multicenter, observational, and prospective study of patients with severe COPD (post-bronchodilator forced expiratory volume in 1 second ≤ 60%). Every consecutive patient, who fulfils the inclusion criteria, is asked to participate in the study. Patient recruitment is done on the basis of signed informed consent. The study was approved by the Multicentre Ethical Committee in Brno, Czech Republic.

Results: The objective of this paper was to outline the methodology of this study.

Conclusion: The establishment of the database is a useful step in improving care for COPD subjects. Additionally, it will serve as a source of data elucidating the natural course of COPD, comorbidities, and overall impact on the patients. Moreover, it will provide information on the diverse course of the COPD syndrome in the Czech Republic.

Keywords: all-cause mortality; comorbidities; exacerbations; phenotypes; prospective study.

Figures

Figure 1
Figure 1
The time schedule of the Czech Multicentre Research Database of Severe COPD. Note: The prospective follow-up period can be extended, if necessary, due to statistical analysis of all-cause mortality. Abbreviation: COPD, chronic obstructive pulmonary disease.
Figure 2
Figure 2
The twelve participating centers in the Czech Republic.

References

    1. Global Initiative for Chronic Obstructive Lung Disease . Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Leuven: Global Initiative for Chronic Obstructive Lung Disease; 2014. [Accessed September 18, 2014]. Available from: .
    1. Ferkol T, Schraufnagel D. The global burden of respiratory disease. Ann Am Thorac Soc. 2014;11(3):404–406.
    1. Patel JG, Nagar SP, Dalal AA. Indirect costs in chronic obstructive pulmonary disease: a review of the economic burden on employers and individuals in the United States. Int J Chron Obstruct Pulmon Dis. 2014;9:289–300.
    1. Fact sheet 315: chronic obstructive pulmonary disease (COPD) [webpage on the Internet] Geneva: World Health Organization; 2008. [Accessed September 18, 2014]. [updated October 2013]. Available from:
    1. Maly M, Zvolsky M, Rozborilova E, Vondra V. Respiratory mortality in Czech and Slovak Republics in the year 2011. Stud Pneumol Phtiseol. 2013;79(4):128–132.
    1. Vondra V. Between 1996 and 2005, COPD mortality has doubled. Stud Pneumol Phtiseol. 2007;73(2):75–77.
    1. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365(13):1184–1192.
    1. Nishimura M, Makita H, Nagai K, et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(1):44–52.
    1. Donaldson GC, Wedzicha JA. COPD exacerbations.1: epidemiology. Thorax. 2006;61(2):164–168.
    1. Miravitlles M, Soler-Cataluna JJ, Calle M, et al. A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC) Prim Care Respir J. 2013;22(1):117–121.
    1. Louie S, Zeki AA, Schivo M, et al. The asthma–chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations. Expert Rev Clin Pharmacol. 2013;6(2):197–219.
    1. Koblizek V, Chlumsky J, Zindr V, et al. Chronic obstructive pulmonary disease: official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013;157(2):189–201.
    1. Ogawa E, Nakano Y, Ohara T, et al. Body mass index in male patients with COPD: correlation with low attenuation areas on CT. Thorax. 2009;64(1):20–25.
    1. Vestbo J, Agusti A, Wouters EF, et al. Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. Am J Respir Crit Care Med. 2014;189(9):1022–1030.
    1. Jones PW, Adamek L, Nadeau G, Banik N. Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification. Eur Respir J. 2013;42(3):647–654.
    1. Jones PW, Brusselle G, Dal Negro RW, et al. Patient-centred assessment of COPD in primary care: experience from a cross-sectional study of health-related quality of life in Europe. Prim Care Respir J. 2012;21(3):329–336.
    1. Ringbaek T, Martinez G, Lange P. A comparison of the assessment of quality of life with CAT, CCQ, and SGRQ in COPD patients participating in pulmonary rehabilitation. COPD. 2012;9(1):12–15.
    1. Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med. 2013;1(1):73–83.
    1. Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):728–735.
    1. Baty F, Putora PM, Isenring B, Blum T, Brutsche M. Comorbidities and burden of COPD: a population based case–control study. PLoS One. 2013;8(5):e63285.
    1. Lazovic B, Mazic S, Stajic Z, Djelic M, Zlatkovic-Svenda M, Putnikovic B. United in prevention-electrocardiographic screening for chronic obstructive pulmonary disease. Acta Inform Med. 2013;21(2):127–128.
    1. Li Y, Shah AJ, Soliman EZ. Effect of electrocardiographic P-wave axis on mortality. Am J Cardiol. 2014;113(2):372–376.
    1. Sievi NA, Clarenbach CF, Camen G, Rossi VA, van Gestel AJ, Kohler M. High prevalence of altered cardiac repolarization in patients with COPD. BMC Pulm Med. 2014;14:55.
    1. Mazurek J, Forfia PR. Enhancing the accuracy of echocardiography in the diagnosis of pulmonary arterial hypertension: looking at the heart to learn about the lungs. Curr Opin Pulm Med. 2013;19(5):437–445.
    1. Rahaghi FN, van Beek EJ, Washko GR. Cardiopulmonary coupling in chronic obstructive pulmonary disease: the role of imaging. Thorac Imaging. 2014;29(2):80–91.
    1. de Miguel Diez J, Chancafe Morgan J, Jimenez Garcia R. The association between COPD and heart failure risk: a review. Int J Chron Obstruct Pulmon Dis. 2013;8:305–312.
    1. Ebner N, Steinbeck L, Doehner W, Anker SD, von Haehling S. Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies. J Cachexia Sarcopenia Muscle. 2014;5(1):27–34.
    1. Kalantar-Zadeh K, Rhee C, Sim JJ, Stenvinkel P, Anker SD, Kovesdy CP. Why cachexia kills: examining the causality of poor outcomes in wasting conditions. J Cachexia Sarcopenia Muscle. 2013;4(2):89–94.
    1. Lainscak M, von Haehling S, Doehner W, et al. Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. J Cachexia Sarcopenia Muscle. 2011;2(2):81–86.
    1. Dam TT, Harrison S, Fink HA, Ramsdell J, Barrett-Connor E. Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma. Osteoporos Int. 2010;21(8):1341–1349.
    1. Hattiholi J, Gaude GS. Bone mineral density among elderly patients with chronic obstructive pulmonary disease patients in India. Niger Med J. 2013;54(5):295–301.
    1. Vazquez E, Mar Gomez Punter R, Giron Moreno R, Sanchez S, Lopez Riolobos C, Ancochea Bermudez J. Biochemical markers of bone turnover in chronic obstructive pulmonary disease (COPD) [abstract] Chest. 2014;145(Suppl 3) abstract 389A.
    1. Romme EA, Smeenk FW, Rutten EP, Wouters EF. Osteoporosis in chronic obstructive pulmonary disease. Expert Rev Respir Med. 2013;7(4):397–410.
    1. Negi H, Sarkar M, Raval AD, Pandey K, Das P. Health-related quality of life in patients with chronic obstructive pulmonary disease in North India. J Postgrad Med. 2014;60(1):7–11.
    1. Miravitlles M, Cantoni J, Naberan K. Factors associated with a low level of physical activity in patients with chronic obstructive pulmonary disease. Lung. 2014;192(2):259–265.
    1. Barriga S, Rodrigues F, Barbara C. Factors that influence physical activity in the daily life of male patients with chronic obstructive pulmonary disease. Rev Port Pneumol. 2014;20(3):131–137.
    1. Tselebis A, Kosmas E, Bratis D, et al. Contribution of psychological factors in dropping out from chronic obstructive pulmonary disease rehabilitation programs. Biomed Res Int. 2014;2014:401326.
    1. Miyazaki M, Nakamura H, Chubachi S, et al. Analysis of comorbid factors that increase the COPD assessment test scores. Respir Res. 2014;15:13.
    1. Wisniewski D, Porzezinska M, Gruchała-Niedoszytko M, Niedoszytko M, Słominski JM, Jassem E. Factors influencing adherence to treatment in COPD patients and its relationship with disease exacerbations. Pneumonol Alergol Pol. 2014;82(2):96–104.
    1. Chrystyn H, Small M, Milligan G, Higgins V, Gil EG, Estruch J. Impact of patients’ satisfaction with their inhalers on treatment compliance and health status in COPD. Respir Med. 2014;108(2):358–365.
    1. Bryant L, Bang C, Chew C, Baik SH, Wiseman D. Adequacy of inhaler technique used by people with asthma or chronic obstructive pulmonary disease. J Prim Health Care. 2013;5(3):191–198.
    1. Coxson HO, Leipsic J, Parraga G, Sin DD. Using pulmonary imaging to move chronic obstructive pulmonary disease beyond FEV1. Am J Respir Crit Care Med. 2014 May 29; Epub.
    1. Mohamed Hoesein FA, Schmidt M, Mets OM, et al. Discriminating dominant computed tomography phenotypes in smokers without or with mild COPD. Respir Med. 2014;108(1):136–143.
    1. de-Torres JP, Casanova C, Marin JM, et al. Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: a pilot study. Respir Med. 2013;107(5):702–707.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe